What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Neuroscience
- Retina
Ivan Bodis-Wollner mostly deals with Neuroscience, Audiology, Dopaminergic, Retinal and Electroretinography.
His Audiology study which covers Sinusoidal grating that intersects with Spatial contrast, Cortex, Visual projection and Sensitivity.
His Dopaminergic study incorporates themes from Levodopa and Parkinson's disease.
His study looks at the relationship between Retinal and topics such as Retina, which overlap with Central nervous system disease.
His Electroretinography study combines topics in areas such as Laser treatment, Laser and Primate.
Ivan Bodis-Wollner has researched Electrophysiology in several fields, including Visual processing and Disease, Pathology.
His most cited work include:
- VISUAL DEFICITS RELATED TO DOPAMINE DEFICIENCY IN EXPERIMENTAL ANIMALS AND PARKINSON'S DISEASE PATIENTS (261 citations)
- Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity. (249 citations)
- Inner retinal layer thinning in Parkinson disease. (200 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Neuroscience, Parkinson's disease, Audiology, Evoked potential and Ophthalmology.
In most of his Neuroscience studies, his work intersects topics such as Retinal.
His study in Parkinson's disease is interdisciplinary in nature, drawing from both Physical therapy, Cognition, Neuropsychology and Degenerative disease.
His Audiology research incorporates themes from Visual perception, Stimulation and Sinusoidal grating.
In his work, Amplitude is strongly intertwined with Spatial frequency, which is a subfield of Evoked potential.
His study focuses on the intersection of Ophthalmology and fields such as Contrast with connections in the field of Visual acuity.
He most often published in these fields:
- Neuroscience (45.32%)
- Parkinson's disease (25.12%)
- Audiology (18.23%)
What were the highlights of his more recent work (between 2009-2020)?
- Parkinson's disease (25.12%)
- Disease (15.27%)
- Neuroscience (45.32%)
In recent papers he was focusing on the following fields of study:
Ivan Bodis-Wollner focuses on Parkinson's disease, Disease, Neuroscience, Retinal and Foveal.
His work deals with themes such as Physical therapy, Severity of illness and Disease monitoring, which intersect with Parkinson's disease.
The various areas that Ivan Bodis-Wollner examines in his Disease study include Family medicine, Dopaminergic, Neurology and Multicenter study.
His multidisciplinary approach integrates Neuroscience and Coherence in his work.
The Retinal study combines topics in areas such as Retina and Pathology.
Ivan Bodis-Wollner combines subjects such as Visual processing and Electrophysiology with his study of Retina.
Between 2009 and 2020, his most popular works were:
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit (183 citations)
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial (135 citations)
- Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease A Randomized Clinical Trial (118 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Neuroscience
- Retina
Ivan Bodis-Wollner mainly investigates Retinal, Physical therapy, Parkinson's disease, Foveola and Retina.
His studies in Physical therapy integrate themes in fields like Unified Parkinson's disease rating scale and Internal medicine, Quality of life.
Parkinson's disease is a subfield of Disease that Ivan Bodis-Wollner studies.
His Foveola research integrates issues from Nerve fiber layer and Inner plexiform layer.
His Retina study contributes to a more complete understanding of Neuroscience.
The concepts of his Ophthalmology study are interwoven with issues in Optometry and Contrast.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
